{
  "items": [
    {
      "title": "Amgen Announces Significant Survival Benefit for Lung Cancer Drug IMDELLTRA in Phase 3 Trial",
      "description": "Amgen Inc. (NASDAQ:AMGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 2, Amgen announced new interim results from the global Phase 3 DeLLphi-304 trial for its drug IMDELLTRA (tarlatamab-dlle). The data were presented at the 2025 ASCO Annual Meeting and published in The New England Journal of Medicine. It [â€¦]",
      "published_utc": "2025-06-15T17:38:44",
      "source": "Yahoo",
      "url": "https://finnhub.io/api/news?id=ade9c6a07583000661c09cc57a6742ec84f2214dc11119de14e60272eb9827bc",
      "category": "company",
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related_symbols": [
        "AMGN"
      ],
      "api_source": "finnhub_company",
      "id": 135285503,
      "datetime": 1749980324
    },
    {
      "id": "907c6524b667598d790d967a711232d50712dc365f87b55afd23fb2cbd7b5a23",
      "publisher": {
        "name": "The Motley Fool",
        "homepage_url": "https://www.fool.com/",
        "logo_url": "https://s3.polygon.io/public/assets/news/logos/themotleyfool.svg",
        "favicon_url": "https://s3.polygon.io/public/assets/news/favicons/themotleyfool.ico"
      },
      "title": "Eli Lilly Just Made Another Move to Dominate the Weight Loss Market: Should You Buy the Stock?",
      "author": "Prosper Junior Bakiny",
      "published_utc": "2025-06-15T11:30:00Z",
      "article_url": "https://www.fool.com/investing/2025/06/15/eli-lilly-made-another-move-to-dominate-the-weight/?source=iedfolrf0000001",
      "tickers": [
        "LLY",
        "AMGN",
        "NVO"
      ],
      "image_url": "https://g.foolcdn.com/editorial/images/820747/patient-sitting-on-hospital-bed.jpg",
      "description": "Eli Lilly is strengthening its position in the weight-management market by partnering with Camurus to develop long-acting delivery of its GLP-1 medicines. This move could make Lilly's treatments more attractive and boost their sales. Lilly also has a deep pipeline and continues to grow its revenue, making it a compelling investment option.",
      "keywords": [
        "Eli Lilly",
        "weight loss",
        "Camurus",
        "GLP-1",
        "long-acting delivery",
        "revenue growth",
        "pipeline"
      ],
      "insights": [
        {
          "ticker": "LLY",
          "sentiment": "positive",
          "sentiment_reasoning": "Eli Lilly is strengthening its position in the weight-management market through a partnership with Camurus, which could improve the delivery and efficacy of its GLP-1 medicines. The company also has a deep pipeline and is experiencing rapid revenue growth, making it an attractive investment option."
        },
        {
          "ticker": "AMGN",
          "sentiment": "neutral",
          "sentiment_reasoning": "The article mentions Amgen's work on a once-monthly anti-obesity therapy, but does not provide a clear assessment of its potential impact on the market."
        },
        {
          "ticker": "NVO",
          "sentiment": "neutral",
          "sentiment_reasoning": "Novo Nordisk is mentioned as Eli Lilly's only real competitor in the weight-management medicines market, but the article does not provide a clear assessment of Novo Nordisk's position or performance."
        }
      ]
    }
  ],
  "metadata": {
    "cached_at": "2025-09-25T07:56:18.907249+00:00",
    "cache_key": "news_a5acb395f3f24720b0221d7340bcfe5c",
    "count": 2
  }
}